Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.43 |
| ▸ | PDE4A | P27815 | 13/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3545894 | 0.84 | PDE4A (0.43) | PDE4BPDE4APDE4CPDE4DUSP2 | |
| SCHEMBL3543999 | 0.84 | PDE4B (0.46) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5197302 | 0.83 | PDE4A (0.41) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3549287 | 0.83 | PDE4A (0.41) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3550836 | 0.82 | PDE4B (0.44) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3550631 | 0.82 | PDE4A (0.55) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL4467048 | 0.81 | PDE4B (0.45) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3544460 | 0.81 | PDE4B (0.47) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5756596 | 0.81 | PDE4A (0.40) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3540011 | 0.81 | PDE4A (0.43) | PDE4BPDE4APDE4CPDE4DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2005-02-03 | — | — | US | claimed |
| US-7696198-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-13 | — | — | US | disclosed |
| WO-2009067607-A2 | COMBINATIONS OF PDE4 INHIBITORS AND ANTIPSYCHOTICS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-05-28 | — | — | WO | disclosed |
| EP-1613590-A2 | 4-(3,4-DISUBSTITUTED PHENYL)-PYRROLIDIN-2-ONE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050026913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2005-02-03 | — | — | US | disclosed |
| WO-2004094375-A2 | 4 - (3,4 - DISUBSTITUTED PHENYL) - PYRROLIDIN-2-ONE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026913-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE12, PDE3B | PDE4B 5/4885PDE4A 1/4885PDE4C 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.